The House on Wednesday passed a bill that would allow dying patients to receive experimental treatments. Here's how, if it passes, the bill would affect providers.
The CMS will now cover diagnostic laboratory tests using gene sequencing technology for Medicare cancer patients. The agency said the tests can help patients and their oncologists make better treatment decisions.
Congress failed to approve a measure that would provide another avenue for terminally ill patients to get access to experimental drugs.
The Food and Drug Administration has approved the first direct-to-consumer breast cancer gene test, but it will require 23andMe to warn consumers about the limitations of the genetic information.
As a healthcare executive long involved in supply-chain procurement for hospitals, I've been flooded with calls from hospital CEOs asking why so many of the pharmaceuticals they need to deliver care are so difficult to secure in sufficient quantities.
The test doesn't detect concussions and the approval won't immediately change how patients with suspected concussions are treated. But it allows Banyan Biomarkers to commercialize its test, giving the company an early lead in the race to find a way to diagnose concussions.
Pharmaceutical stocks dipped Thursday following the announcement that four large health systems will partner to create a not-for-profit generic drug company.
Combating the opioid crisis and promoting greater generic drug competition are among a set of the FDA's top policy priorities for 2018 the agency released this week.
Anthem's CEO Gail Boudreaux, FDA Commissioner Dr. Scott Gottlieb and Optum CEO Larry Renfro are among top healthcare leaders who are likely to have a large impact on the industry in 2018.
Congress is going home for the holidays, but lawmakers have left plenty of unfinished business. And the specter of big-picture health reform lingers.
The Food and Drug Administration has given makers of antiseptics used in healthcare settings one year to remove triclosan from their products after the agency deemed it and other ingredients no more safe or effective than using plain soap and water.
In response to the 21st Century Cures Act, the FDA outlined its regulatory approach in guidance documents about software as a medical device.